THE ROLE OF HEMOGRAM IN DISTINGUISHING PROSTATE CANCER AND BENIGN PROSTATIC HYPERPLASIA

Creative Commons License

Mertoğlu C., Katırcı H. C.

EuroMedLab 2025 , Brussels, Belçika, 18 - 22 Mayıs 2025, cilt.63, ss.2553, (Özet Bildiri)

  • Yayın Türü: Bildiri / Özet Bildiri
  • Cilt numarası: 63
  • Doi Numarası: 10.1515/cclm-2025-8069
  • Basıldığı Şehir: Brussels
  • Basıldığı Ülke: Belçika
  • Sayfa Sayıları: ss.2553
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • İnönü Üniversitesi Adresli: Evet

Özet

THE ROLE OF HEMOGRAM IN DISTINGUISHING PROSTATE CANCER AND BENIGN PROSTATIC HYPERPLASIA

C. Mertoglu 1, H.C. Katırcı 1 1Inonu University Medical Biochemistry

BACKGROUND-AIM Definitive differentiation between prostate cancer and benign prostatic hyperplasia(BPH) is only possible through histopathological examination. Serum prostate specific antigen(PSA) test used before biopsy has low sensitivity and specificity. In this study, hemogram parameters and indices derived from them were compared with the PSA.

METHODS Laboratory information system records were examined and the initial test results (excluding repeated subsequent tests) of patients diagnosed with prostate cancer (n=939) and BPH (n=9139) who applied to the outpatient clinic in the last 5 (January 1, 2019-December 31, 2024) years were compared. Neutrophil-to-lymphocyte ratio(NLR) was calculated as neutrophil/ lymphocyte, platelet-to-lymphocyte ratio(PLR) as platelet/lymphocyte, and SII as systemic immuneinflammation index (platelet × neutrophil/lymphocyte).

RESULTS We compared the prostate cancer group and the BPH group, listing the mean ± standard deviation values in this order, respectively. Age(69.7±8.69 years, 61.6±12.6, p<0.001), total PSA(tPSA)(19.7±86.3 ng/mL, 4.44±10.5, p<0.001), free PSA(fPSA)(2.69±7.77 ng/mL, 0.966±1.75, p<0.001), NLR(2.84±2.25, 2.56±2.13, p<0.001), PLR( 145±89.9, 127±61.8, p<0.001), SII(744±816, 657±637, p<0.001), red cell distribution width–coefficient of variation(RDW-CV)(14.0±1.88 %, 13.5±1.54, p<0.001) were higher in prostate cancer patients compared to BPH group, whereas fPSA/tPSA(0.251±0.160, 0.302±0.145, p< 0.001), hemoglobin(Hb)(13.5±1.96 g/dL, 14.6±1.71, p<0.001) hematocrit(Hct)(41.3±5.43 %, 44.5±4.63, p< 0.001) and red blood cell(RBC)(4.72±0.651 106/ µL, 5.09±0.572, p<0.001) count were lower. In receiver operating characteristic(ROC) analysis, area under the curve (AUC) values were found as; tPSA; 0.551, fPSA; 0.571, fPSA/tPSA; 0.625, NLR; 0.553, PLR; 0.563, SII; 0.539, Hb and Hct; 0.683, RBC; 0.673, RDW-CV; 0.598.

CONCLUSIONS Prostate cancer patients have higher subclinical inflammation compared to BPH patients. Also, complete blood count parameters may be useful in distinguishing prostate cancer and BPH